Scientists at the Sahlgrenska Academy have developed a new cancer treatment that has proved to be effective in mice. The treatment, which is presented in the prestigious scientific journal PNAS, is based on newly discovered properties of the so-called BET bromodomain inhibitors.
A few years ago, a molecule known as “JQ1” was developed, which can block so called BET bromodomain proteins. This switch off the known cancer gene MYC thereby preventing cancer cells from dividing.
Jonas Nilsson, Sahlgrenska Cancer Center at the University of Gothenburg
The discovery was regarded as a major breakthrough. A problem was that JQ1 did not function optimally in animal experiments, and this means that it has not been possible to test the treatment on cancer patients.
Jonas Nilsson and his research group have developed, in collaboration with the Canadian company Zenith epigenetics, a new molecule known as “RVX2135”, which has been tested in mice with MYC-driven lymphoma. The study will be published this week in the early edition of the prestigious scientific journal PNAS and shows that the new molecule not only causes cancer cells in culture to stop growing, it also causes tumors to die. This means that the mice survive their cancer longer.
“We hypothesized that the new molecule could also switch off the MYC gene. However, our studies show that neither the JQ1 molecule nor the RVX2135 molecule have this property in these types of cells. This means that the mode of action is probably not as simple as we believed,” says Jonas Nilsson, Group Leader at the Sahlgrenska Cancer Center.
Increased survival in mice
The scientists in Gothenburg also discovered that the RVX2135 molecule activates the same genes as those activated by molecules known as “HDAC inhibitors”, which are already used to treat cancer. The scientists then tested HDAC inhibitors together with the newly discovered molecules and it turned out that the combination increased survival in mice with lymphoma.
“It was also possible to reduce the dose of HDAC inhibitors when used in combination with RVX2135 and this reduced adverse effects. We see this as a breakthrough in the clinical development of this type of treatment,” Jonas Nilsson explains.
Jonas Nilsson has recently founded the Sahlgrenska Translational Melanoma Group together with surgeons and oncologists at the Sahlgrenska University Hospital. This group will investigate whether the treatment can be used also for malignant melanoma.
“The work is challenging, but we believe that the prospects for success with combination treatments are good,” says Jonas Nilsson.
The article BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma will be published online in Proceedings of the National Academy of Sciences on 16 June.
Link to article: http://www.pnas.org/content/early/2014/06/13/1406722111.abstract
More information about the research project: http://www.cancercenter.gu.se/research/nilsson-lab/
Jonas Nilsson, Sahlgrenska Cancer Center at the Sahlgrenska Academy, University of Gothenburg
Tel.: +46 31 786 6768
Cell: +46 73 027 3039
Henrik Axlid | idw - Informationsdienst Wissenschaft
Penn researchers use network science to help pinpoint source of seizures
29.01.2016 | University of Pennsylvania
Automobiles increase the mobility of their users. However, their maneuverability is pushed to the limit by cramped inner city conditions. Those who need to...
Advance in biomedical imaging: The University of Würzburg's Biocenter has enhanced fluorescence microscopy to label and visualise up to nine different cell structures simultaneously.
Fluorescence microscopy allows researchers to visualise biomolecules in cells. They label the molecules using fluorescent probes, excite them with light and...
NASA's follow-on to the successful ICESat mission will employ a never-before-flown technique for determining the topography of ice sheets and the thickness of sea ice, but that won't be the only first for this mission.
Slated for launch in 2018, NASA's Ice, Cloud and land Elevation Satellite-2 (ICESat-2) also will carry a 3-D printed part made of polyetherketoneketone (PEKK),...
In the last decades, sea level has been rising continuously – about 3.3 mm per year. For reef islands such as the Maldives or the Marshall Islands a sinister picture is being painted evoking the demise of the island states and their cultures. Are the effects of sea-level rise already noticeable on reef islands? Scientists from the ZMT have now answered this question for the Takuu Atoll, a group of Pacific islands, located northeast of Papua New Guinea.
In the last decades, sea level has been rising continuously – about 3.3 mm per year. For reef islands such as the Maldives or the Marshall Islands a sinister...
The ‘Internet of Things’ is growing rapidly. Mobile phones, washing machines and the milk bottle in the fridge: the idea is that minicomputers connected to these will be able to process information, receive and send data. This requires electrical power. Transistors that are capable of switching information with a single electron use far less power than field effect transistors that are commonly used in computers. However, these innovative electronic switches do not yet work at room temperature. Scientists working on the new EU research project ‘Ions4Set’ intend to change this. The program will be launched on February 1. It is coordinated by the Helmholtz-Zentrum Dresden-Rossendorf (HZDR).
“Billions of tiny computers will in future communicate with each other via the Internet or locally. Yet power consumption currently remains a great obstacle”,...
02.02.2016 | Event News
26.01.2016 | Event News
26.01.2016 | Event News
05.02.2016 | Life Sciences
05.02.2016 | Materials Sciences
05.02.2016 | Physics and Astronomy